It has been established for a number of topically applied inhibitors that block HIV at or soon after the entry stages that full efficacy in vivo requires concentrations many orders of magnitude higher than the in vitro IC50 [5,25-28].
It has been established for a number of topically appliedinhibitors that block HIV at or soon after the entry stages that full efficacy in vivo requires concentrations many orders of magnitude higher than the in vitro IC50 [5,25-28].